Physician profile
Cheryl Foucher
NPI 1801335567
$2,349.90
in general payments reported to CMS, 2019-2025
28 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.48 · 2020: $139 · 2021: $232 · 2022: $707 · 2023: $655 · 2024: $244 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $452.87 | 2021-2023 | Ova1 |
| Abbvie INC. | $262.60 | 2019-2023 | |
| Biogen, INC. | $187.81 | 2024-2025 | Zurzuvae |
| Organon LLC | $182.91 | 2022-2024 | Nexplanon |
| Hologic Sales and Service, LLC | $169.21 | 2022-2025 | Acessa Provu System, Fluent Fluid Management System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Ethicon US, LLC | $135.57 | 2023 | Stratafix |
| Sumitomo Pharma America, INC. | $129.95 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $122.38 | 2020-2022 | |
| Myovant Sciences INC. | $82.60 | 2022 | |
| Pfizer INC. | $71.81 | 2021-2023 | |
| Coloplast Corp | $68.68 | 2023-2024 | Restorelle |
| Bayer Healthcare Pharmaceuticals INC. | $49.67 | 2022-2023 | |
| Conmed Corporation | $42.78 | 2021 | |
| Daiichi Sankyo INC. | $41.41 | 2022-2023 | Injectafer |
| Heron Therapeutics, INC. | $40.56 | 2022-2023 | Zynrelef |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $40.38 | 2022-2024 | Paragard T 380a |
| Exeltis, USA INC. | $36.54 | 2022-2025 | Slynd |
| Exact Sciences Corporation | $32.62 | 2023 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $31.02 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.55 | 2023 | Gvoke Hypopen |
| Integra Lifesciences Corporation | $23.28 | 2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Minerva Surgical, INC | $20.44 | 2023 | |
| Medicem INC. | $20.04 | 2023 | |
| Agile Therapeutics, INC. | $18.67 | 2022 | |
| Lilly USA, LLC | $18.58 | 2022 | |
| Octapharma USA, INC. | $15.63 | 2025 | Fibryga |
| Sage Therapeutics, LLC | $13.67 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $13.67 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Foucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.